0.7577 USD
+0.03 (+4.81%)
0.7349 USD
-0.02 (-3.01%)
We assign a fundamental rating of 3 out of 10 to HBIO. HBIO was compared to 58 industry peers in the Life Sciences Tools & Services industry. HBIO may be in some trouble as it scores bad on both profitability and health. HBIO is cheap, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year HBIO was profitable.
HBIO had a positive operating cash flow in the past year.
In the past 5 years HBIO always reported negative net income.
HBIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
HBIO has a Return On Assets of -69.03%. This is amonst the worse of the industry: HBIO underperforms 87.93% of its industry peers.
HBIO's Return On Equity of -382.68% is on the low side compared to the rest of the industry. HBIO is outperformed by 87.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROIC | N/A |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HBIO's Gross Margin of 56.94% is fine compared to the rest of the industry. HBIO outperforms 74.14% of its industry peers.
In the last couple of years the Gross Margin of HBIO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for HBIO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
2. Health
2.1 Basic Checks
HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
HBIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HBIO has more shares outstanding
HBIO has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.63, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.63, HBIO is doing worse than 82.76% of the companies in the same industry.
There is no outstanding debt for HBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Altman-Z | -2.63 |
ROIC/WACCN/A
WACC11.06%
2.3 Liquidity
A Current Ratio of 0.81 indicates that HBIO may have some problems paying its short term obligations.
HBIO has a worse Current ratio (0.81) than 93.10% of its industry peers.
HBIO has a Quick Ratio of 0.81. This is a bad value and indicates that HBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
HBIO has a Quick ratio of 0.41. This is amonst the worse of the industry: HBIO underperforms 96.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 |
3. Growth
3.1 Past
HBIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
HBIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -19.73% yearly.
Looking at the last year, HBIO shows a very negative growth in Revenue. The Revenue has decreased by -10.60% in the last year.
The Revenue has been decreasing by -4.12% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
3.2 Future
Based on estimates for the next years, HBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 45.77% on average per year.
Based on estimates for the next years, HBIO will show a decrease in Revenue. The Revenue will decrease by -1.21% on average per year.
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.94 indicates a rather expensive valuation of HBIO.
Based on the Price/Earnings ratio, HBIO is valued cheaper than 91.38% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.46, HBIO is valued a bit cheaper.
A Price/Forward Earnings ratio of 5.94 indicates a rather cheap valuation of HBIO.
Based on the Price/Forward Earnings ratio, HBIO is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
HBIO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.10.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.94 | ||
| Fwd PE | 5.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HBIO is valued cheaply inside the industry as 94.83% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than HBIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.95 | ||
| EV/EBITDA | 13.45 |
4.3 Compensation for Growth
A more expensive valuation may be justified as HBIO's earnings are expected to grow with 45.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.77%
EPS Next 3YN/A
5. Dividend
5.1 Amount
HBIO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.7577
+0.03 (+4.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners58.21%
Inst Owner Change-12.33%
Ins Owners3.72%
Ins Owner Change9.91%
Market Cap33.78M
Revenue(TTM)87.37M
Net Income(TTM)-53.84M
Analysts80
Price Target2.04 (169.24%)
Short Float %3.45%
Short Ratio0.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-49.02%
Min EPS beat(2)-100%
Max EPS beat(2)1.96%
EPS beat(4)3
Avg EPS beat(4)-1.23%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-39.49%
EPS beat(12)5
Avg EPS beat(12)-32.85%
EPS beat(16)5
Avg EPS beat(16)-35.95%
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)0.94%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)2
Avg Revenue beat(8)-3.88%
Revenue beat(12)3
Avg Revenue beat(12)-4.45%
Revenue beat(16)3
Avg Revenue beat(16)-4.48%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)-12.5%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.94 | ||
| Fwd PE | 5.94 | ||
| P/S | 0.39 | ||
| P/FCF | 4.95 | ||
| P/OCF | 3.95 | ||
| P/B | 2.4 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.45 |
EPS(TTM)0.04
EY5.28%
EPS(NY)0.13
Fwd EY16.83%
FCF(TTM)0.15
FCFY20.19%
OCF(TTM)0.19
OCFY25.31%
SpS1.96
BVpS0.32
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.03% | ||
| ROE | -382.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.94% | ||
| FCFM | 7.81% |
ROA(3y)-6.27%
ROA(5y)-4.8%
ROE(3y)-12.47%
ROE(5y)-9.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.75%
GM growth 5Y0.96%
F-Score4
Asset Turnover1.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 4.98 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 27.22% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 193.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.41 | ||
| Altman-Z | -2.63 |
F-Score4
WACC11.06%
ROIC/WACCN/A
Cap/Depr(3y)33.21%
Cap/Depr(5y)26.48%
Cap/Sales(3y)2.31%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y-37.86%
EPS 5Y-19.73%
EPS Q2Q%100%
EPS Next Y-57.5%
EPS Next 2Y45.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.6%
Revenue growth 3Y-7.49%
Revenue growth 5Y-4.12%
Sales Q2Q%-6.28%
Revenue Next Year-8.8%
Revenue Next 2Y-1.21%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4466.67%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.1%
OCF growth 3Y4.55%
OCF growth 5Y-29.12%
HARVARD BIOSCIENCE INC / HBIO FAQ
What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a fundamental rating of 3 / 10 to HBIO.
What is the valuation status of HARVARD BIOSCIENCE INC (HBIO) stock?
ChartMill assigns a valuation rating of 7 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Undervalued.
Can you provide the profitability details for HARVARD BIOSCIENCE INC?
HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.
What is the expected EPS growth for HARVARD BIOSCIENCE INC (HBIO) stock?
The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -57.5% in the next year.